The FreeStyle Libre portfolio helped reduce HbA1c*†1-13, hypoglycemia*†14-15, work absenteeism*†16-17, and resource utilization*†18-21, among patients with type 1 and type 2 diabetes.
See outcome categories below for further details.
Using CGM to gain glucose insights can lead to meaningful changes in diabetes outcomes.
The FreeStyle Libre portfolio helped reduce HbA1c*†1-13, hypoglycemia*†14-15, work absenteeism*†16-17, and resource utilization*†18-21, among patients with type 1 and type 2 diabetes.
See outcome categories below for further details.
“95-OR: Impact of Flash Glucose Monitoring in People with Type 2 Diabetes Inadequately Controlled with Noninsulin Antihyperglycemic Therapy: IMMEDIATE study”*1
Brown RE, et al. Diabetes (2022): https://doi.org/10.2337/db22-95-OR
“Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis”*2
Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590
“74-LB: Sustainable HbA1c Decrease at 12 Months for Adults with Type 1 and Type 2 Diabetes Using the FreeStyle Libre System: A Study within the National Diabetes Register in Sweden”*3
Eeg-Olofsson K, et al. Diabetes (2020): https://doi.org/10.2337/db20-74-LB
“Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies”*4
Evans M, et al. Diabetes Ther (2022): https://doi.org/10.1007/s13300-022-01253-9
“Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes”*5
Leelarathna L, et al. N Engl J Med (2022): https://doi.org/10.1056/nejmoa2205650
“The Impact of Flash Glucose Monitoring on Glycated Hemoglobin in Type 2 Diabetes Managed with Basal Insulin in Canada: A Retrospective Real-World Chart Review Study”*6
Elliott T, et al. Diabetes Vasc Dis Res (2021): https://doi.org/10.1177/14791641211021374
“Use of Flash Continuous Glucose Monitoring Is Associated with A1c Reduction in People with Type 2 diabetes Treated with Basal Insulin or Noninsulin Therapy”*7
Wright E, et al. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069
“Three European Retrospective Real-world Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes”*8
Kroger J, et al. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9
“HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy”*9
Miller E, et al. Diabetes (2020): https://doi.org/10.2337/db20-84-LB
“Flash Glucose Monitoring Helps Achieve Better Glycemic Control than Conventional Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes: A Randomized Controlled Trial”*10
Wada E, et al. BMJ Open Diabetes Res Care (2020): https://doi.org/10.1136/bmjdrc-2019-001115
“Marked Improvement in HbA1c Following Commencement of Flash Glucose Monitoring in People with Type 1 Diabetes”*11
Tyndall V, et al. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1
“Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes”*12
Yaron M, et al. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166
“Outcomes of Using Flash Glucose Monitoring Technology by Children and Young People with Type 1 Diabetes in a Single-arm Study”*13
Campbell F, et al. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735
“Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: A Multicenter, Open-Label Randomized Controlled Trial”*14
Haak T, et al. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6
“Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: A Multicentre, Non-masked, Randomised Controlled Trial”*15
Bolinder J, et al. Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5
“Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study”*16
Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610
“Improved Well-being and Decreased Disease Burden After 1-year use of Flash Glucose Monitoring (FLARE-NL4)”*17
Fokkert M, et al. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809
“Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France”*18
Guerci B, et al. Diabetes Technol Ther (2022): https://doi.org/10.1089/dia.2022.0271
“Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes”*19
Bergenstal R, et al. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013
“Flash CGM Associated With Event Reduction in Nonintensive Diabetes Therapy”20
Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780
“Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit”*21
Deshmukh H, et al. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738
“193 / Abstract ID 334 - CGM Use Associated with Reduction in Acute Diabetes Complications, Even in Patients Using Less Than Four Test Strips per Day”*22
Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts
“Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study”*16
Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610
“Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)”*†17
Fokkert M, et al. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809
Get in touch with our Medical Affairs team to learn more about the latest clinical evidence supporting the FreeStyle Libre portfolio.
Medicare and other payor criteria may apply.
* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 system has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. FreeStyle Libre 3 system has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
† Data from this study was collected with the outside US version of the FreeStyle Libre 2 system. FreeStyle Libre 3 system has the same features as FreeStyle Libre 2 system with real-time glucose alarms. Therefore the study data is applicable to both products.
References: 1. Brown RE, et al. Diabetes (2022): https://doi.org/10.2337/db22-95-OR 2. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 3. Eeg-Olofsson K, et al. Diabetes (2020): https://doi.org/10.2337/db20-74-LB 4. Evans M, et al. Diabetes Ther (2022): https://doi.org/10.1007/s13300-022-01253-9 5. Leelarathna L, et al. N Engl J Med (2022): https://doi.org/10.1056/nejmoa2205650 6. Elliott T, et al. Diabetes Vasc Dis Res (2021): https://doi.org/10.1177/14791641211021374 7. Wright E, et al. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 8. Kroger J, et al. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9 9. Miller E, et al. Diabetes (2020): https://doi.org/10.2337/db20-84-LB 10. Wada E, et al. BMJ Open Diabetes Res Care (2020): https://doi.org/10.1136/bmjdrc-2019-001115 11. Tyndall V, et al. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 12. Yaron M, et al. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166 13. Campbell F, et al. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 14. Haak T, et al. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 15. Bolinder J, et al. Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 16. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 17. Fokkert M, et al. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 18. Guerci B, et al. Diabetes Technol Ther (2022): https://doi.org/10.1089/dia.2022.0271 19. Bergenstal R, et al. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 20. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 21. Deshmukh H, et al. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738 22. Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts
ADC-76904 v3.0
Important Safety Information
FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-85718 v2.0
Payer.freestylelibre.us/en is a product-specific website intended only for residents of the United States.
If you are a resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.
ADC-21099 v3.0 07/21
Stay connected